MTOR and cystic fibrosis: Rapamycin mediated mTOR inhibition has been shown to reduce lung inflammatory responses in a CF mouse model (Abdulrahman et al., 2011), along with improved CFTR function (Luciani et al., 2011; Tazi and Amer, 2015).